Pancreatic Cancer Research

ResearcherMemorial Sloan Kettering Cancer CenterActive in the last 2 years

Richard Kinh Gian

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-6554-0310; OpenAlex author ID A5058483454, A5103931067. Sources: ClinicalTrials.gov.

Their work

Papers
23 (first author 0, last author 6)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
85
Papers, trials and grants by year

2015: 1 paper · 2016: 1 paper · 2017: 1 paper · 2018: 4 papers · 2019: 1 paper · 2020: 2 papers · 2021: 3 papers · 2022: 1 paper · 2023: 4 papers · 2024: 1 paper · 2025: 1 paper · 2026: 3 papers, 1 trial

Papers 23

  1. Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial. Co-author DOI 10.1038/s41591-026-04299-5↗
  2. NRG1 fusion-positive solid tumors: clinical detection, genomic landscape, and real-world data in pancreatic cancer. Co-author DOI 10.1093/jnci/djaf361↗
  3. Tumor Microenvironment: Insights from Multiparametric MRI in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers18020273↗
  4. Factors Associated With Aborted Whipple Procedures for Periampullary Carcinoma: A Multicenter Case-Control Study by the SAR Pancreatic Ductal Adenocarcinoma Di… Co-author DOI 10.2214/ajr.24.32160↗
  5. CT Surveillance for Local Recurrence After Pancreatic Cancer Resection: Evaluation of Imaging Findings From the SAR Disease-Focused Panel Consensus Statement. Last author DOI 10.2214/ajr.24.31563↗
  6. Postoperative surveillance of pancreatic ductal adenocarcinoma (PDAC) recurrence: practice pattern on standardized imaging and reporting from the society of ab… Co-author DOI 10.1007/s00261-022-03693-0↗
  7. Phase 1 Dose Escalation Study of SBRT Using 3 Fractions for Locally Advanced Pancreatic Cancer. Co-author DOI 10.1016/j.ijrobp.2023.03.036↗
  8. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Co-author DOI 10.1038/s41586-023-06063-y↗
  9. Registration-based biomarkers for neoadjuvant treatment response of pancreatic cancer via longitudinal image registration. Co-author DOI 10.1117/1.jmi.10.3.036002↗
  10. Recurrence After Resection of Pancreatic Cancer: Can Radiomics Predict Patients at Greatest Risk of Liver Metastasis? Co-author DOI 10.1245/s10434-022-11579-0↗
  11. Preoperative CT predictors of survival in patients with pancreatic ductal adenocarcinoma undergoing curative intent surgery. Last author DOI 10.1007/s00261-020-02726-w↗
  12. Radiomics for CT Assessment of Vascular Contact in Pancreatic Adenocarcinoma. Co-author DOI 10.1148/radiol.2021211635↗
  13. Longitudinal Monitoring of Simulated Interstitial Fluid Pressure for Pancreatic Ductal Adenocarcinoma Patients Treated with Stereotactic Body Radiotherapy. Co-author DOI 10.3390/cancers13174319↗
  14. Therapeutic response assessment in pancreatic ductal adenocarcinoma: society of abdominal radiology review paper on the role of morphological and functional im… Co-author DOI 10.1007/s00261-020-02723-z↗
  15. Diffusion-Weighted and Dynamic Contrast-Enhanced MRI Derived Imaging Metrics for Stereotactic Body Radiotherapy of Pancreatic Ductal Adenocarcinoma: Preliminar… Co-author DOI 10.18383/j.tom.2020.00015↗
  16. CT radiomics associations with genotype and stromal content in pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s00261-019-02112-1↗
  17. Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adeno… Co-author DOI 10.1002/cncr.31218↗
  18. Can physician gestalt predict survival in patients with resectable pancreatic adenocarcinoma? Co-author DOI 10.1007/s00261-017-1407-x↗
  19. Incidence, Management, and Implications of Visceral Thrombosis in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.clcc.2018.01.008↗
  20. Survival Prediction in Pancreatic Ductal Adenocarcinoma by Quantitative Computed Tomography Image Analysis. Last author DOI 10.1245/s10434-017-6323-3↗
  21. Imaging for pancreatic ductal adenocarcinoma. Last author DOI 10.21037/cco.2017.11.03↗
  22. Imaging comparison of tubular and colloid pancreatic adenocarcinoma arising from intraductal papillary mucinous neoplasm on multidetector CT. Last author DOI 10.1016/j.clinimag.2016.08.011↗
  23. FOLFIRINOX Induction Therapy for Stage 3 Pancreatic Adenocarcinoma. Co-author DOI 10.1245/s10434-015-4647-4↗

Trials 1

  1. A Study of Magnetic Resonance Imaging of the Pancreas for Cancer Screening Principal investigator NCT07612046↗

Closest collaborators

The 25 strongest of 85 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Eileen Mary O'Reilly · 7 shared papers, 2015–2026 · strength 1.00
  2. Amita Shukla‐Dave · 4 shared papers, 2020–2026 · strength 0.68
  3. William R. Jarnagin · 7 shared papers, 2015–2023 · strength 0.67
  4. Avinash R. Kambadakone · 4 shared papers, 2020–2025 · strength 0.67
  5. Ramesh Paudyal · 3 shared papers, 2020–2026 · strength 0.53
  6. T. Peter Kingham · 6 shared papers, 2015–2022 · strength 0.50
  7. Michael Ian D'Angelica · 6 shared papers, 2015–2022 · strength 0.50
  8. Shannan M. Dickinson · 3 shared papers, 2021–2024 · strength 0.47
  9. Peter J. Allen · 6 shared papers, 2015–2022 · strength 0.47
  10. Vinod P. Balachandran · 5 shared papers, 2018–2022 · strength 0.45
  11. Amber L. Simpson · 5 shared papers, 2018–2022 · strength 0.45
  12. Jayasree Chakraborty · 4 shared papers, 2018–2023 · strength 0.45
  13. Karyn A. Goodman · 4 shared papers, 2015–2023 · strength 0.44
  14. Marsha Reyngold · 3 shared papers, 2020–2023 · strength 0.40
  15. Alice Chia-Chi Wei · 2 shared papers, 2023–2024 · strength 0.40
  16. Zhen J. Wang · 3 shared papers, 2020–2025 · strength 0.39
  17. Marc Zins · 3 shared papers, 2020–2025 · strength 0.39
  18. Erik V. Soloff · 3 shared papers, 2020–2025 · strength 0.39
  19. Atif Zaheer · 3 shared papers, 2020–2025 · strength 0.39
  20. Olca Baştürk · 2 shared papers, 2019–2026 · strength 0.32
  21. Caitlin A. McIntyre · 3 shared papers, 2019–2022 · strength 0.30
  22. Jeffrey A. Drebin · 3 shared papers, 2019–2022 · strength 0.30
  23. Jin Peng He · 2 shared papers, 2023–2025 · strength 0.29
  24. Samuel Joseph Galgano · 2 shared papers, 2023–2025 · strength 0.29
  25. Lyndon Luk · 2 shared papers, 2023–2025 · strength 0.29

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.